What is the clinical evidence from this study?

Study design: Observational. Population: Coronary artery disease or stroke (n=171). Intervention: Unfavorable CYP2C19 genotypes (*1/*2, *2/*17, and *2/*2) vs. Favorable CYP2C19 genotypes (*1/*1, *1/*17, and *17/*17). Primary outcome: Clopidogrel resistance (p=0.059).

What does this research mean for the field?

In Mexican mestizo patients with atherosclerosis, the prevalence of CYP2C19 polymorphisms is similar to the general population, and these genetic variants alone do not fully explain in vitro clopidogrel resistance. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

September 1, 2026BiomedicinesOpen Access

Frequencies of CYP2C19 Polymorphisms in Mexican Mestizo Patients with Coronary or Cerebral Atherosclerosis and Their Association with Residual Platelet Activity on Clopidogrel Treatment

View Full Paper

Ask AI

Bookmark

Why the study?

Do CYP2C19 polymorphisms predict clopidogrel resistance in Mexican mestizo patients with coronary or cerebral atherosclerosis?

Population

171 Mexican mestizo patients receiving clopidogrel treatment.

Comparison

CYP2C19 genotyping and platelet aggregation… vs Favorable genotypes vs. unfavorable genotypes…

Design

Cross-sectional

Key result

Unfavorable CYP2C19 genotypes showed a non-significant trend toward higher clopidogrel resistance compared to favorable genotypes (64.7% vs 39.1%; p=0.059).

Authors

RIRaúl Izaguirre-Ávila BVBeatriz Villegas-Torres ECEvelyn Cortina-de-la-Rosa

Discussion

Member takes

Overview

CYP2C19 variants may predict clopidogrel response in Mexican mestizos; leaves open whether genotyping improves outcomes in this population.

Study Design

Type

Observational (n=171)

Structured PICO

Do CYP2C19 polymorphisms predict clopidogrel resistance in Mexican mestizo patients with coronary or cerebral atherosclerosis?

Population

171 Mexican mestizo patients with coronary artery disease or stroke receiving clopidogrel, of whom 81 were tested for platelet aggregation.

Exposure

CYP2C19 genotyping (*1, *2, *3, and *17 alleles) and platelet aggregation testing

Comparator

Favorable genotypes (CYP2C19 *1/*1, *1/*17, and *17/*17) vs. unfavorable genotypes for metabolism (CYP2C19 *1/*2, *2/*17, and *2/*2)

Outcome

Prevalence of CYP2C19 polymorphisms and clopidogrel resistance assessed by ADP-induced aggregation in platelet-rich plasmasurrogate

Main Result

Absolute Event Rate: 64.7% vs 39.1%

p-value: p=0.059

In Mexican mestizo patients, CYP2C19 polymorphisms alone do not fully explain in vitro clopidogrel resistance, which appears to be a complex multifactorial phenomenon.

Cite This Study

Izaguirre-Ávila et al. (2026) conducted an observational in Coronary artery disease or stroke (n=171). Unfavorable CYP2C19 genotypes (*1/*2, *2/*17, and *2/*2) vs. Favorable CYP2C19 genotypes (*1/*1, *1/*17, and *17/*17) was evaluated on Clopidogrel resistance (p=0.059). Unfavorable CYP2C19 genotypes showed a non-significant trend toward higher clopidogrel resistance compared to favorable genotypes (64.7% vs 39.1%; p=0.059).

synapsesocial.com/papers/6a9926b3f3ae593e0136346f https://doi.org/10.3390/biomedicines14091970

View Full Paper

Ask AI

Bookmark

September 1, 2026BiomedicinesOpen Access

Frequencies of CYP2C19 Polymorphisms in Mexican Mestizo Patients with Coronary or Cerebral Atherosclerosis and Their Association with Residual Platelet Activity on Clopidogrel Treatment

View Full Paper

Ask AI

Bookmark

Why the study?

Do CYP2C19 polymorphisms predict clopidogrel resistance in Mexican mestizo patients with coronary or cerebral atherosclerosis?

Population

171 Mexican mestizo patients receiving clopidogrel treatment.

Comparison

CYP2C19 genotyping and platelet aggregation… vs Favorable genotypes vs. unfavorable genotypes…

Design

Cross-sectional

Key result

Unfavorable CYP2C19 genotypes showed a non-significant trend toward higher clopidogrel resistance compared to favorable genotypes (64.7% vs 39.1%; p=0.059).

Authors

RIRaúl Izaguirre-Ávila BVBeatriz Villegas-Torres ECEvelyn Cortina-de-la-Rosa

Discussion

Member takes

Overview

CYP2C19 variants may predict clopidogrel response in Mexican mestizos; leaves open whether genotyping improves outcomes in this population.

Study Design

Type

Observational (n=171)

Structured PICO

Do CYP2C19 polymorphisms predict clopidogrel resistance in Mexican mestizo patients with coronary or cerebral atherosclerosis?

Population

171 Mexican mestizo patients with coronary artery disease or stroke receiving clopidogrel, of whom 81 were tested for platelet aggregation.

Exposure

CYP2C19 genotyping (*1, *2, *3, and *17 alleles) and platelet aggregation testing

Comparator

Favorable genotypes (CYP2C19 *1/*1, *1/*17, and *17/*17) vs. unfavorable genotypes for metabolism (CYP2C19 *1/*2, *2/*17, and *2/*2)

Outcome

Prevalence of CYP2C19 polymorphisms and clopidogrel resistance assessed by ADP-induced aggregation in platelet-rich plasmasurrogate

Main Result

Absolute Event Rate: 64.7% vs 39.1%

p-value: p=0.059

In Mexican mestizo patients, CYP2C19 polymorphisms alone do not fully explain in vitro clopidogrel resistance, which appears to be a complex multifactorial phenomenon.

Cite This Study

synapsesocial.com/papers/6a9926b3f3ae593e0136346f https://doi.org/10.3390/biomedicines14091970

View Full Paper

Ask AI

Bookmark